65 years of age when compared with patients between 45 and 64 years of age. 4 As a result of this increasing rate of lumbar fusions, expansion of indications, and complexity of surgery, the socioeconomic impact has become more closely scrutinized, requiring that medical evidence justify the application of these procedures.
In 2005, the first iteration of the "Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine" was published in the Journal of Neurosurgery: Spine. 5 This comprehensive compendium outlined 16 topics pertaining to the performance of lumbar fusion surgery for degenerative spinal disease, providing 50 recommendations based on a review of the medical literature published between 1966 and 2003. Given the time dependency of a literature review, clinical practice guidelines are evolving documents that require periodic updating as new information and knowledge accumulates. The purpose of the current series, "Guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine," is to incorporate the more recent medical evidence that has been published since the original publication and establish new recommendations.
In 2009, an expert panel of neurosurgical and orthopedic spine surgeons was convened, many having participated in the original guidelines effort. All members had experience with clinical guideline development and had completed the evidence-based medicine course developed by the North American Spine Society (NASS). As the current document is to serve as an update, identical topics and search terms were selected from the original guideline publication.
Methodology
The development of evidence-based clinical guidelines is a multistep process, the basis of which has been well described. 3 The current update was constructed through a series of steps, similar to the previous guideline efforts:
1. Selection of topics to study a. As this is an update, the same topics from the original guidelines were chosen. 2. Performing a literature search a. Searches were limited to English studies investigating human subjects. 3. Collecting relevant studies for review a. Searches were reviewed and studies specifically investigating the topic under consideration were chosen. 4. Assessing the quality and strength of the evidence a. Modified NASS strategy 5. Formulation of recommendations based on the evidence a. Modified NASS strategy 6. Panel review of the evidentiary tables a. Consensus method used to establish uniformity of response 7. Submission of guidelines for peer review As previously stated, the first two steps were based on the topics and search terms used in the original guideline submission.
The literature searches were conducted with the assistance of a librarian who had extensive experience formulating and conducting evidence-based literature searches. Search terms from the original guidelines were used and altered as deemed necessary. Searches of the National Library of Medicine and Cochrane database were conducted from the termination of the original searches, in 2003, through December of 2011. The abstracts were reviewed and all relevant publications were selected for formal assessment. Bibliographies were reviewed from selected publications and appropriate studies selected. The specifics of each search, including the MeSH terms, are described in each chapter.
Topics were assigned to individual panel members, with the primary assignee intended to perform the assessment of evidence and a second panel member intended to review the evidentiary table prior to presentation to the entire panel. Each assignee formulated preliminary recommendations based on their review of the literature. The expert panel completed final determination of the levels of evidence and recommendation grades after reviewing the evidentiary tables.
In an effort to conform to spine guidelines published from other clinical societies, as well as maintain an objective assessment of the evidence, the current panel elected to deviate from the methodology employed in the original guidelines and use the NASS strategy for evidence assessment and recommendation grading (see Tables 1 and  2 ). As there are no uniformly accepted methods for downgrading evidence, the panel decided to limit downgrading of evidence by no more than one level to avoid excessive subjectivity.
As the current publication is intended to serve as an update of the previous guidelines, the decision was made to include all Level I and II evidence from the original guidelines. A reevaluation of these studies utilizing the NASS strategy was necessary. The panel agreed not to include lower levels of evidence, as these studies were not likely to enhance the updated recommendations.
Quality of Medical Evidence
The foundation for any evidence-based practice guidelines rests on the assessment of medical evidence. The NASS assessment of medical evidence is a 5-tiered strategy that assigns separate levels to "case series" and "expert opinion" (see Table 1 ). This highlights the major difference between the 3-tiered approach used in the original guideline publication, where the decision was made to combine all lower levels of evidence. This distinction becomes relevant when grading recommendations.
Each study was categorized according to the underlying objective-therapeutic, diagnostic, or prognostic. The initial level of evidence was determined by defining the overall study design. For example, a randomized control trial would start as Level I evidence while a retrospective review could start no higher than Level III. The study's methodology was then analyzed to determine if the nec-essary criteria were fulfilled to maintain the initial level of evidence. These criteria were in part based on the NASS strategy as well as the panel's scientific and clinical experience and are listed in Table 3 . Downgrading of therapeutic studies occurred if at least 1 major or 2 minor limitations were identified. For the other study categories, these criteria were considered as well as those specifically outlined in Table 3 .
Studies that met all criteria and contained data that would significantly alter current medical practice would be upgraded; however, no study met these criteria. During the panel review of the evidentiary tables, consensus method was used to resolve any disagreement. 2 Ultimately, the panel achieved unanimous agreement for every study evaluated in the evidentiary tables.
Formulation of Treatment Recommendations
The primary investigator for a given topic, prior to the consensus development process, formulated preliminary recommendations. During panel discussions the decision was made as to which studies would serve as the basis for the final recommendations, and these studies were included within the "Scientific Foundation" for a given topic. In general, if high-quality evidence (Level I and II data) was available to formulate a recommendation, lesser-quality evidence was not included. Studies of low quality that conflicted with high-quality evidence were not included in the evidentiary tables, but this discrepancy was mentioned in the "Scientific Foundation."
The expert panel assigned a grade to each recom- Table 3 for listing of major and minor limitations of study design utilized to determine level of medical evidence. RCT = randomized controlled trial. Table 2 ). The baseline NASS strategy was used, but modifications were included to address instances in which a single study provided evidence for a specific recommendation. The highest-quality recommendation, Grade "A," required 2 or more Level I studies with consistent findings. Fair evidence, either a single Level I study or consistent findings from multiple Level II or III studies, was given a Grade "B" recommendation. Poor-quality evidence would support a Grade "C" recommendation, including either a single Level II study or consistent findings from Level IV or V studies. Recommendations based on a single Level III or lower-level study or studies of equal strength that demonstrated conflicting results were given a Grade "I" designation.
Summary
As greater emphasis is placed on validating the surgical treatments for our patients, particularly with regard to spine surgery, the necessity for evidence-based clinical guidelines is becoming increasing apparent. Given the time dependency of a literature review, all clinical practice guidelines are evolving documents that require periodic updating. As an update, the current publication was intended to build on the foundation established by the original lumbar fusion guidelines. After careful evaluation, the current expert panel felt it necessary to reconsider the methodology of previous guidelines. These changes were incorporated in an effort to perform a more objective evaluation and allow for easier communication among clinicians from other subspecialty organizations.
Although emphasis has recently been placed on evidence-based clinical practice and improving the method of scientific investigation, the panel frequently encountered studies of inferior quality. Despite this limitation, one objective of the current update is to identify areas of future research and stimulate more objective clinical investigation. It is the hope that the well-informed reader will carefully evaluate the "Scientific Foundation" to understand the justification for a given recommendation. As with previous guideline efforts, there is a risk of specialty bias as no nonsurgical stakeholders were involved in the development of this update. Although the potential for this bias exists, considerable effort was taken to try and objectively evaluate the current literature.
These guidelines are not intended to provide rigid treatment algorithms. Instead, it is hoped that this update will serve as a comprehensive review of the current state of the literature and provide the reader with a foundation to formulate an appropriate individualized treatment plan for a given patient. Furthermore it is the intent of any guideline to identify current limitations of the literature and stimulate further investigational research.
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